Search Technologies

The National Cancer Institute (NCI) seeks research and co-development partners and/or licensees for chimeric antigen receptors (CARs) targeting the B-cell antigen CD22

Researchers at the National Cancer Institute (NCI) developed a DNA vaccine using conserved elements of HIV-1 Gag, administered in a prime-boost vaccination protocol. Two of the HIV Gag CE DNA vectors have been tested in a rhesus macaque model. Priming with the Gag CE vaccine and boosting with full length Gag DNA showed increased immune responses when compared to vaccination with Gag alone. Researchers seek licensing and/or co-development research collaborations for development this DNA vaccine.

Inventors at the National Cancer Institute (NCI) have developed chimeric antigen receptors (CARs) that target two B cell surface antigens, CD19 and CD22, improving treatment of B-cell malignancies, such as acute lymphoblastic leukemia (ALL). NCI is actively seeking parties interested in licensing this invention to commercialize the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.

NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) for early-stage cancer detection, and significantly decrease expensive false negative/false positive results. The NCI seeks co-developers or licensees to commercialize this technology.

This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.

Researchers at the National Cancer Institute identified a collection of TCRs that exclusively recognize the common hotspot driver mutations in p53 tumor suppressor, expressed by a variety of human cancers, including colorectal, breast and lung cancers. The mutated p53 variants are recognized by the TCRs in the context of specific Class I/Class II HLA alleles. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.'

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E7. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.